June 10 Financial Quick Takes: Vivo raises $1.3B for ninth fund; plus Prevail, Dermavant, Akero set terms for IPOs

Vivo has at least $1.3B for next fund
Vivo Capital has raised $1.3 billion toward its ninth fund from 36 investors, according to an SEC filing. The healthcare investment firm did not disclose in the filing the total amount it is seeking to raise.

Three biotechs set IPO ranges
Prevail, Dermavant and Akero proposed ranges for their respective NASDAQ IPOs Monday, which could raise a combined total of $300.1 million. All three companies initially filed to list in May (see "New IPO Filings Include BridgeBio, Dermavant, Prevail, Atreca, Akero")...